Selective Sodium Channel Blockade to Deliver Clinical Efficacy in Refractory Chronic Cough

  • Selective local targeting of cough nociceptors to provide meaningful clinical outcomes in patients with refractory chronic cough
  • Interpreting Phase 2b clinical data to understand exposure response relationships, tolerability & efficacy
  • Achieving sufficient local exposure in lung tissue while avoiding systemic liability
  • Human proof of concept for selective sodium channel blockade to de-risk respiratory ion channel development